Skip to main content
Premium Trial:

Request an Annual Quote

Australia s Cryptome to Use Northeastern University s Proteomics Technology

NEW YORK, April 6 (GenomeWeb News) - Cryptome Pharmaceuticals, a Melbourne, Australia-based drug discovery firm, said today that it has signed an agreement with NortheasternUniversity to use proteomics technology developed at the university.

 

Cryptome said it will use technology developed by William Hancock at Northeastern, which identifies and isolates low-abundance human proteins.

 

Hancock is a member of Cryptome's scientific advisory board.

 

Cryptome said that the methodology will augment its own discovery platform, which uses high-throughput screening to identify peptides of natural proteins that have previously unrecognized potential as therapeutic drugs.

 

Cryptome will retain all commercial rights to new drug candidates developed as part of the collaboration.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.